XM does not provide services to residents of the United States of America.
M
M

McKesson


News

Thousands turn to Wegovy copies each month as FDA considers shortage status

EXCLUSIVE-Thousands turn to Wegovy copies each month as FDA considers shortage status More than 200,000 prescriptions for Wegovy alternatives are filled in the U.S. each month FDA is weighing whether to remove Wegovy from its shortage list Pharmacy compounding group has asked FDA to consider its data when making a decision By Patrick Wingrove Nov 25 (Reuters) - More than 200,000 prescriptions for copies of Novo Nordisk's NOVOb.CO weight-loss drug Wegovy are getting filled by U.S.
M

Activist investor Ananym Capital pushes for changes at Henry Schein, sources say

EXCLUSIVE-Activist investor Ananym Capital pushes for changes at Henry Schein, sources say Ananym Capital urges board changes, CEO succession plan, cost cuts Ananym says medical distribution business sale could increase stock price by 20% Ananym has recruited potential board directors, sources say Adds stock move in paragraph 3, Henry Schein comment in paragraph 7 By Svea Herbst-Bayliss NEW YORK, Nov 18 (Reuters) - Activist investor Ananym Capital Management is urging healthcare products distrib
M

Activist investor Ananym Capital pushes for changes at Henry Schein, sources say

EXCLUSIVE-Activist investor Ananym Capital pushes for changes at Henry Schein, sources say Ananym Capital urges board changes, CEO succession plan, cost cuts Ananym says medical distribution business sale could increase stock price by 20% Ananym has recruited potential board directors, sources say By Svea Herbst-Bayliss NEW YORK, Nov 18 (Reuters) - Activist investor Ananym Capital Management is urging healthcare products distributor Henry Schein HSIC.O to refresh its board, cut costs, tackle suc
M

Baltimore wins $266 million in opioid case against distributors

Baltimore wins $266 million in opioid case against distributors By Brendan Pierson Nov 13 (Reuters) - The city of Baltimore won $266 million in its lawsuit accusing top drug distributors McKesson MCK.N and Cencora COR.N of fueling an epidemic of opioid addiction in the U.S., and is expected to seek billions more in the next phase of the case. A six-person jury in the Circuit Court for Baltimore found McKesson responsible for $192 million and Cencora for $74 million on Tuesday following a nearly
W
M

S&P 500 top and bottom performing stocks at about 02:30 p.m. EST

BUZZ - S&P 500 top and bottom performing stocks at about 02:30 p.m. EST S&P 500 .SPX Top Performers Percent Change Viatris Inc VTRS.OQ +14.9% Epam Systems Inc EPAM.N +14% Super Micro Computer Inc SMCI.OQ +11.5% Mckesson Corp MCK.N +11.3% Warner Bros Discovery Inc WBD.OQ +11.0% Bottom Performers Percent Change Match Group Inc MTCH.OQ -17.6% APA Corp
M
U
M
C
S

U.S. STOCKS Ralph Lauren, CoreCivic, WK Kellogg

BUZZ-U.S. STOCKS ON THE MOVE-Ralph Lauren, CoreCivic, WK Kellogg Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes held on to their gains on Thursday in the run-up to the Federal Reserve's interest-rate decision, extending a sharp rally sparked by Donald Trump's stunning comeback as U.S.
G
H
J
K
M
D
U
U
B
M
V
A
C
M

Mckesson Corp reports results for the quarter ended in September 30 - Earnings Summary

Mckesson Corp reports results for the quarter ended in September 30 - Earnings Summary Mckesson Corp MCK.N reported quarterly adjusted earnings of $7.07​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $6.23. The mean expectation of sixteen analysts for the quarter was for earnings of $6.88 per share.
M

McKesson raises annual profit forecast on strength in its U.S. pharma segment

McKesson raises annual profit forecast on strength in its U.S. pharma segment Nov 6 (Reuters) - Drug distributor McKesson Corp MCK.N raised its annual profit forecast on Wednesday, driven by increased sales in its U.S. pharmaceuticals segment on robust demand for specialty and branded drugs. Shares of the company were up 4.5% in extended trading. The Texas-headquartered company now expects 2025 profit in the range of $32.40 to $33 per share, compared with its previous estimate of $31.75 and $32.
M

McKesson Q2 Adjusted EPS USD 7.07 Vs. IBES Estimate USD 6.88

BRIEF-McKesson Q2 Adjusted EPS USD 7.07 Vs. IBES Estimate USD 6.88 Nov 06 (Reuters) - McKesson Q2 adjusted net income USD 915 million vs. IBES estimate USD 891.8 million. Q2 operating income USD 578 million Q2 revenue USD 93,651 million vs. IBES estimate USD 89,330 million Q2 EPS USD 1.87 outlook FY adjusted EPS USD 32.4-33
M

Cencora bolsters specialty business with $4.6 bln deal for Retina Consultants of America

UPDATE 2-Cencora bolsters specialty business with $4.6 bln deal for Retina Consultants of America Adds details on deal throughout, earnings details in paragraphs 8-11, analyst comment in paragraph 5 Nov 6 (Reuters) - Cencora COR.N will buy Retina Consultants of America from private-equity firm Webster Equity Partners for $4.6 billion, the drug distributor said on Wednesday, beefing up its presence in the market for specialty medicines.
M

What to Watch in the Day Ahead - Wednesday, November 6

What to Watch in the Day Ahead - Wednesday, November 6 The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at DAY/US . Thomson One users can register at RT/DAY/US. All times in ET/GMT The Federal Reserve will begin its two-day monetary policy meeting and is expected to continue policy easing measures that began in September with a bumper 50-basis-point rate cut.
N
Q
T
L
M
U

Cardinal Health lifts annual profit outlook on strength in specialty medicines unit

UPDATE 1-Cardinal Health lifts annual profit outlook on strength in specialty medicines unit Adds comments from conf call in paragraphs 4,8,9 details in paragraph 7 By Mariam Sunny Nov 1 (Reuters) - Cardinal Health CAH.N raised its fiscal 2025 adjusted profit forecast on Friday as strong demand for costly specialty medicines and branded drugs drove sales at its pharmaceuticals unit, sending shares of the company up nearly 7%.
M

Cardinal Health lifts annual profit outlook on strength in specialty medicines unit

Cardinal Health lifts annual profit outlook on strength in specialty medicines unit Nov 1 (Reuters) - Cardinal Health CAH.N raised its 2025 adjusted profit forecast on Friday as strong demand for costly specialty medicines and branded drugs drove sales at its pharmaceuticals unit, sending the shares of the company up nearly 4% in premarket trading.
M

Mckesson Says Ontada Collaborates With Microsoft To Transform Unstructured Oncology Data With Azure OpenAI Technology

BRIEF-Mckesson Says Ontada Collaborates With Microsoft To Transform Unstructured Oncology Data With Azure OpenAI Technology Oct 17 (Reuters) - Mckesson Corp MCK.N : MCKESSON: ONTADA COLLABORATES WITH MICROSOFT TO TRANSFORM UNSTRUCTURED ONCOLOGY DATA WITH AZURE OPENAI TECHNOLOGY Further company coverage: MCK.N
M
M

U.S. Costco Wholesale, McKesson, Starbucks

CORRECTED-U.S. RESEARCH ROUNDUP-Costco Wholesale, McKesson, Starbucks Corrects named item code to RCH/US from RCH/EUROPE, the same error was there in a previous version of the U.S. research roundup Sept 24 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Costco Wholesale, McKesson and Starbucks, on Tuesday.
C
R
S
M
C
L

Costco Wholesale, McKesson, Starbucks

CORRECTED-US RESEARCH ROUNDUP-Costco Wholesale, McKesson, Starbucks Corrects named item code to RCH/US from RCH/EUROPE; a previous version was corrected to fix headline tag to US RESEARCH ROUNDUP from EUROPE RESEARCH ROUNDUP and to change media packaging code to RESEARCH-US/ Sept 24 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Costco Wholesale, McKesson and Starbucks on Tuesday.
C
S
M
C
L

Cardinal Health to acquire Integrated Oncology Network for $1.12 billion

UPDATE 2-Cardinal Health to acquire Integrated Oncology Network for $1.12 billion Adds details and background throughout Sept 20 (Reuters) - Cardinal Health CAH.N on Friday agreed to acquire community cancer center operator Integrated Oncology Network for $1.12 billion in cash, marking its expansion into cancer care. The Dublin, Ohio-based company is the latest to join the trend of healthcare service companies diversifying beyond drug distribution.
M

Baltimore to take drug distributors to trial over opioids

UPDATE 1-Baltimore to take drug distributors to trial over opioids Adds comment from Cencora in paragraph 4 By Brendan Pierson Sept 16 (Reuters) - The city of Baltimore is scheduled to go to trial this week in its $11 billion lawsuit accusing drug distributors McKesson MCK.N and Cencora COR.N of fueling an epidemic of opioid addiction and overdose deaths.
T
W
M

Baltimore to take drug distributors to trial over opioids

CORRECTED-Baltimore to take drug distributors to trial over opioids Corrects headline and lead, adds paragraphs 4-5 to state that J&J settled before trial By Brendan Pierson Sept 16 (Reuters) - The city of Baltimore is scheduled to go to trial this week in its $11 billion lawsuit accusing drug distributors McKesson MCK.N and Cencora COR.N of fueling an epidemic of opioid addiction and overdose deaths.
T
W
M

Baltimore settles with Teva, Walgreens ahead of scheduled opioid trial

UPDATE 1-Baltimore settles with Teva, Walgreens ahead of scheduled opioid trial Adds comment from J&J in paragraph 6 By Brendan Pierson Sept 10 (Reuters) - Baltimore said on Tuesday that it has settled with Walgreens WBA.O over claims that the pharmacy operator fueled opioid addiction in the Maryland city, the latest in a series of settlements totaling $402.5 million ahead of a trial scheduled to begin next week.
T
W
M



Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.